Shandong Pharmaceutical Glass Co Ltd (600529) - Net Assets
Based on the latest financial reports, Shandong Pharmaceutical Glass Co Ltd (600529) has net assets worth CN¥8.29 Billion CNY (≈ $1.21 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.04 Billion ≈ $1.47 Billion USD) and total liabilities (CN¥1.75 Billion ≈ $255.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600529 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.29 Billion |
| % of Total Assets | 82.58% |
| Annual Growth Rate | 16.43% |
| 5-Year Change | 77.6% |
| 10-Year Change | 172.53% |
| Growth Volatility | 35.9 |
Shandong Pharmaceutical Glass Co Ltd - Net Assets Trend (1999–2025)
This chart illustrates how Shandong Pharmaceutical Glass Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Shandong Pharmaceutical Glass Co Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Shandong Pharmaceutical Glass Co Ltd (1999–2025)
The table below shows the annual net assets of Shandong Pharmaceutical Glass Co Ltd from 1999 to 2025. For live valuation and market cap data, see 600529 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.29 Billion ≈ $1.21 Billion |
+3.58% |
| 2024-12-31 | CN¥8.01 Billion ≈ $1.17 Billion |
+6.28% |
| 2023-12-31 | CN¥7.53 Billion ≈ $1.10 Billion |
+8.23% |
| 2022-12-31 | CN¥6.96 Billion ≈ $1.02 Billion |
+49.06% |
| 2021-12-31 | CN¥4.67 Billion ≈ $683.41 Million |
+9.74% |
| 2020-12-31 | CN¥4.26 Billion ≈ $622.77 Million |
+10.03% |
| 2019-12-31 | CN¥3.87 Billion ≈ $565.98 Million |
+9.70% |
| 2018-12-31 | CN¥3.53 Billion ≈ $515.92 Million |
+8.47% |
| 2017-12-31 | CN¥3.25 Billion ≈ $475.62 Million |
+6.79% |
| 2016-12-31 | CN¥3.04 Billion ≈ $445.37 Million |
+36.03% |
| 2015-12-31 | CN¥2.24 Billion ≈ $327.41 Million |
+5.26% |
| 2014-12-31 | CN¥2.13 Billion ≈ $311.04 Million |
+4.71% |
| 2013-12-31 | CN¥2.03 Billion ≈ $297.05 Million |
+4.62% |
| 2012-12-31 | CN¥1.94 Billion ≈ $283.93 Million |
+4.90% |
| 2011-12-31 | CN¥1.85 Billion ≈ $270.68 Million |
+5.98% |
| 2010-12-31 | CN¥1.75 Billion ≈ $255.40 Million |
+9.55% |
| 2009-12-31 | CN¥1.59 Billion ≈ $233.14 Million |
+9.68% |
| 2008-12-31 | CN¥1.45 Billion ≈ $212.56 Million |
+11.16% |
| 2007-12-31 | CN¥1.31 Billion ≈ $191.22 Million |
+41.31% |
| 2006-12-31 | CN¥924.74 Million ≈ $135.32 Million |
+7.33% |
| 2005-12-31 | CN¥861.57 Million ≈ $126.08 Million |
+8.08% |
| 2004-12-31 | CN¥797.19 Million ≈ $116.65 Million |
+9.92% |
| 2003-12-31 | CN¥725.23 Million ≈ $106.12 Million |
+11.52% |
| 2002-12-31 | CN¥650.32 Million ≈ $95.16 Million |
+189.88% |
| 2001-12-31 | CN¥224.34 Million ≈ $32.83 Million |
+19.12% |
| 2000-12-31 | CN¥188.33 Million ≈ $27.56 Million |
+18.61% |
| 1999-12-31 | CN¥158.78 Million ≈ $23.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Pharmaceutical Glass Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7534.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.20 Billion | 50.67% |
| Common Stock | CN¥663.61 Million | 8.00% |
| Other Comprehensive Income | CN¥782.33 Million | 9.43% |
| Other Components | CN¥2.65 Billion | 31.90% |
| Total Equity | CN¥8.29 Billion | 100.00% |
Shandong Pharmaceutical Glass Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Pharmaceutical Glass Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LandBridge Company LLC
NYSE:LB
|
$1.81 Billion |
|
Relay Therapeutics Inc
NASDAQ:RLAY
|
$1.81 Billion |
|
Hunan TV & Broadcast Intermediary Co Ltd
SHE:000917
|
$1.81 Billion |
|
Pavilion Real Estate Inv Trust
KLSE:5212
|
$1.81 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
$1.81 Billion |
|
Wondershare Technology Co Ltd Class A
SHE:300624
|
$1.81 Billion |
|
Lingyun Ind
SHG:600480
|
$1.81 Billion |
|
Tongyu Heavy Industry
SHE:300185
|
$1.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Pharmaceutical Glass Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,007,769,690 to 8,294,642,156, a change of 286,872,466 (3.6%).
- Net income of 689,626,040 contributed positively to equity growth.
- Dividend payments of 370,341,793 reduced retained earnings.
- Other comprehensive income increased equity by 59,379,148.
- Other factors decreased equity by 91,790,929.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥689.63 Million | +8.31% |
| Dividends Paid | CN¥370.34 Million | -4.46% |
| Other Comprehensive Income | CN¥59.38 Million | +0.72% |
| Other Changes | CN¥-91.79 Million | -1.11% |
| Total Change | CN¥- | 3.58% |
Book Value vs Market Value Analysis
This analysis compares Shandong Pharmaceutical Glass Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 53.37x to 1.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | CN¥0.35 | CN¥18.64 | x |
| 2000-12-31 | CN¥0.42 | CN¥18.64 | x |
| 2001-12-31 | CN¥0.49 | CN¥18.64 | x |
| 2002-12-31 | CN¥1.46 | CN¥18.64 | x |
| 2003-12-31 | CN¥1.63 | CN¥18.64 | x |
| 2004-12-31 | CN¥1.80 | CN¥18.64 | x |
| 2005-12-31 | CN¥1.94 | CN¥18.64 | x |
| 2006-12-31 | CN¥2.11 | CN¥18.64 | x |
| 2007-12-31 | CN¥2.67 | CN¥18.64 | x |
| 2008-12-31 | CN¥2.90 | CN¥18.64 | x |
| 2009-12-31 | CN¥3.15 | CN¥18.64 | x |
| 2010-12-31 | CN¥3.47 | CN¥18.64 | x |
| 2011-12-31 | CN¥3.63 | CN¥18.64 | x |
| 2012-12-31 | CN¥3.88 | CN¥18.64 | x |
| 2013-12-31 | CN¥4.06 | CN¥18.64 | x |
| 2014-12-31 | CN¥4.16 | CN¥18.64 | x |
| 2015-12-31 | CN¥4.38 | CN¥18.64 | x |
| 2016-12-31 | CN¥6.06 | CN¥18.64 | x |
| 2017-12-31 | CN¥5.48 | CN¥18.64 | x |
| 2018-12-31 | CN¥5.91 | CN¥18.64 | x |
| 2019-12-31 | CN¥6.50 | CN¥18.64 | x |
| 2020-12-31 | CN¥7.15 | CN¥18.64 | x |
| 2021-12-31 | CN¥7.85 | CN¥18.64 | x |
| 2022-12-31 | CN¥11.60 | CN¥18.64 | x |
| 2023-12-31 | CN¥11.36 | CN¥18.64 | x |
| 2024-12-31 | CN¥12.06 | CN¥18.64 | x |
| 2025-12-31 | CN¥12.51 | CN¥18.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Pharmaceutical Glass Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.31%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.41%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.21x
- Recent ROE (8.31%) is below the historical average (10.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 18.41% | 12.18% | 0.65x | 2.31x | CN¥12.86 Million |
| 2000 | 16.75% | 10.39% | 0.74x | 2.17x | CN¥12.27 Million |
| 2001 | 17.34% | 10.67% | 0.75x | 2.17x | CN¥15.82 Million |
| 2002 | 8.53% | 12.96% | 0.45x | 1.47x | CN¥-9.40 Million |
| 2003 | 9.80% | 15.00% | 0.45x | 1.45x | CN¥-1.40 Million |
| 2004 | 9.62% | 13.51% | 0.45x | 1.57x | CN¥-2.99 Million |
| 2005 | 9.70% | 12.27% | 0.47x | 1.68x | CN¥-2.57 Million |
| 2006 | 10.41% | 11.62% | 0.51x | 1.77x | CN¥3.74 Million |
| 2007 | 8.51% | 11.20% | 0.53x | 1.43x | CN¥-19.50 Million |
| 2008 | 9.79% | 12.26% | 0.58x | 1.37x | CN¥-3.10 Million |
| 2009 | 9.08% | 11.62% | 0.56x | 1.39x | CN¥-14.66 Million |
| 2010 | 9.84% | 11.32% | 0.60x | 1.45x | CN¥-2.84 Million |
| 2011 | 7.16% | 9.49% | 0.56x | 1.35x | CN¥-52.44 Million |
| 2012 | 6.18% | 8.16% | 0.56x | 1.35x | CN¥-74.21 Million |
| 2013 | 6.03% | 7.92% | 0.57x | 1.33x | CN¥-80.66 Million |
| 2014 | 5.89% | 7.37% | 0.60x | 1.33x | CN¥-86.93 Million |
| 2015 | 6.52% | 8.44% | 0.58x | 1.33x | CN¥-77.48 Million |
| 2016 | 6.23% | 9.22% | 0.53x | 1.28x | CN¥-114.76 Million |
| 2017 | 8.08% | 11.27% | 0.56x | 1.29x | CN¥-62.27 Million |
| 2018 | 10.16% | 13.86% | 0.56x | 1.31x | CN¥5.64 Million |
| 2019 | 11.86% | 15.33% | 0.58x | 1.34x | CN¥71.91 Million |
| 2020 | 13.26% | 16.47% | 0.61x | 1.32x | CN¥138.85 Million |
| 2021 | 12.66% | 15.25% | 0.60x | 1.37x | CN¥124.06 Million |
| 2022 | 8.88% | 14.77% | 0.48x | 1.26x | CN¥-77.88 Million |
| 2023 | 10.30% | 15.57% | 0.53x | 1.24x | CN¥22.35 Million |
| 2024 | 11.78% | 18.40% | 0.51x | 1.27x | CN¥142.21 Million |
| 2025 | 8.31% | 15.41% | 0.45x | 1.21x | CN¥-139.84 Million |
Industry Comparison
This section compares Shandong Pharmaceutical Glass Co Ltd's net assets metrics with peer companies in the Packaging & Containers industry.
Industry Context
- Industry: Packaging & Containers
- Average net assets among peers: $1,510,655,620
- Average return on equity (ROE) among peers: 6.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Pharmaceutical Glass Co Ltd (600529) | CN¥8.29 Billion | 18.41% | 0.21x | $1.81 Billion |
| Zhuhai Zhongfu Enterprise Co Ltd (000659) | $606.44 Million | 3.69% | 3.09x | $758.20 Million |
| Huangshan Novel Co Ltd (002014) | $698.53 Million | 14.41% | 0.40x | $1.00 Billion |
| Shenzhen Jinjia Color Printing Group Co Ltd (002191) | $2.42 Billion | 9.27% | 0.55x | $805.15 Million |
| Xiamen Hexing Packaging Printing Co Ltd (002228) | $77.58 Million | 15.90% | 1.27x | $692.47 Million |
| Shenzhen Beauty Star Co Ltd (002243) | $1.56 Billion | 2.86% | 0.23x | $1.51 Billion |
| Zhejiang Great Southeast Co Ltd (002263) | $508.59 Million | 3.43% | 2.86x | $1.11 Billion |
| Shenzhen MYS Environmental Protection & Technology Co Ltd (002303) | $4.45 Billion | 7.83% | 0.33x | $761.87 Million |
| Shandong Lipeng Co Ltd (002374) | $537.39 Million | 5.62% | 0.26x | $511.34 Million |
| Zhejiang Zhongcheng Packing Material Co Ltd (002522) | $1.98 Billion | 1.81% | 0.57x | $841.65 Million |
| Shanghai Luxin Packing Materials Science&Technology Co Ltd (002565) | $2.27 Billion | 4.33% | 0.64x | $2.95 Billion |
About Shandong Pharmaceutical Glass Co Ltd
Shandong Pharmaceutical Glass Co.Ltd engages in research and development, production, and sale of various pharmaceutical glass packaging products in China. The company offers moulded glass products, including amber glass containers, dropper bottles, infusion bottles, cosmetic bottles, tablet bottle, food glass, cobalt blue and green bottles, and black bottles, as well as moulded glass injection v… Read more